Compare GSK plc (GSK) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Tapestry, Inc. — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Tapestry, Inc. trades at $116.27 (market cap $23.09B). The key difference: GSK plc is far larger — about 4× Tapestry, Inc.'s market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Tapestry, Inc. for 70 Days on average.
| GSK | TPR | |
|---|---|---|
Market Cap | $91.88B | $23.09B |
Volume | 7,730,529 | 2,745,259 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $164.78 |
52-Week Low | $43.24 | $98.81 |
Typical Hold Time | 93 Days | 70 Days |
Enterprise Value | $111.88B | $25.89B |
Dividend Yield | 3.9% | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
TPR trades at $116.24, up 2.51% today, showing strong momentum after recent earnings beats. The stock faces technical resistance near $117-119 but maintains bullish analyst support with a $174.64 consensus target. Recent financials show revenue growth to $7.01B in 2025, though net income declined to $183M. The company benefits from strong brand performance with Coach driving growth, while expanding digital presence through Google partnerships.
Outlook remains positive with 73% analyst buy ratings and projected 2026 revenue of $8B. Key risks include Kate Spade execution challenges, tariff pressures, and premium valuation at 15.93 P/E. The stock offers 50% upside to consensus target but requires monitoring of margin expansion and international growth execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
